Senti Biosciences Holdings (SNTI) Short-term Investments (2022 - 2023)
Senti Biosciences Holdings (SNTI) posted quarterly Short-term Investments of $22.9 million for Q2 2023, down 48.58% quarter-over-quarter from $44.5 million in Q1 2023.
Senti Biosciences Holdings (SNTI) Short-term Investments (2022 - 2023) Analysis & Trends
Senti Biosciences Holdings' Short-term Investments history runs 2 years deep, the most recent figure standing at $22.9 million for Q2 2023.
- In Q2 2023, Short-term Investments changed N/A year-over-year to $22.9 million; the TTM figure through Jun 2023 stood at $22.9 million (changed N/A YoY), while the FY2022 annual figure was $40.9 million, changed N/A from the prior year.
- Short-term Investments for Q2 2023 stood at $22.9 million, down from $44.5 million in the prior quarter.
- The five-year high for Short-term Investments was $44.5 million in Q1 2023, with the low at $22.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 22.88 Mn |
| Mar 31, 2023 | 44.51 Mn |
| Dec 31, 2022 | 40.94 Mn |